Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Peringkat dalam Saham #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Harga Saham
$0.4264
Terakhir disinkronkan: 2022-09-14
Kapitalisasi Pasar
$7.93M
Perubahan (1 hari)
-16.44%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Caladrius Biosciences, Inc. (CLBS)

Kategori

Riwayat hasil dividen untuk Caladrius Biosciences, Inc. (CLBS)
Hasil dividen (TTM) dari Caladrius Biosciences, Inc. (simbol saham: CLBS) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Caladrius Biosciences, Inc. (CLBS) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing